Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

 Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Shots:

  • The P-II study involves assessing of BI 425809 (4 oral doses, qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP Congress
  • Results: met its 1EPs and showed improvement in cognition in stable adult schizophrenia patients. The results are being further evaluated in cognitive impairment associated with schizophrenia
  • BI 425809 is an orally administered, glycine transporter-1 inhibitor and a key component of Boehringer Ingelheim’s CNS research program. The results along with an ongoing combination P-II study of BI 425809 and adjunctive computerized cognitive training, will help determine the direction for BI 425809 in further schizophrenia research

Click here ­to­ read full press release/ article | Ref: Buisness wire | Image: GMP News

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post